Tempus AI, Inc. (TEM): Short-Term Debt to Equity Ratio

Symbol and logo of brand Tempus (TEM)

Clinical data automation via an AI platform optimizes therapy selection, and this chart on GURU.Markets reflects that the short-term debt-to-equity dynamics currently carry a value of 0.15. Tempus AI, Inc (TEM) monetizes genetic databases to develop targeted drugs within the B2B segment, although the company faces intense pressure from tech behemoths and major diagnostic networks.

TEM (Tempus) Current Liabilities to Capital history from 06/15/2024 to 10/28/2026

Metric breakdowns and analytics for Tempus AI Inc (TEM)

- price and consensus price forecast:
Stock Price Tempus AI|TEM - Analyst Consensus Forecast
- market capitalization data:
Market Valuation Tempus AI, Inc.|TEM - Aggregate Business Value
- book capitalization data:
Book Value per Share Tempus|TEM - Total Stockholders' Equity|Market Value to Book Value Ratio tempus.com|TEM - Cumulative Company Assets
- debt and liquidity data:
Debt to Equity Tempus AI, Inc|TEM - Long-Term Liabilities to Equity|Short-Term Debt to Equity Ratio Tempus Labs|TEM - Company Aggregate Debts|Debt to Book Capitalization Ratio Tempus AI, Inc.|TEM - Long-Term Debt Volume|Company Current Liabilities Tempus
General company analysis:tempus.com, TEM
Mass-produced product of Tempus AI, Inc

Tempus AI, Inc (TEM) is scaling the integration of AI into diagnostics by leveraging the expansion of clinical databases. The ratio of current liabilities to equity determines the ability of assets to cover short-term debts due within one year. An analysis of the trend of short-term loans relative to equity reveals hidden liquidity risks during business expansion. Low indicator values confirm financial stability, which is critical for long-term growth in medtech.

Competitors of Tempus AI, Inc

Short-Term Debt to Capital QGEN|Short-Term Debt to Capital Isis Pharmaceuticals IONS|Short-Term Debt to Equity Ratio Repligen Corporation (RGEN)|Short-Term Loans to Capital Ratio aviditybiosciences.com RNA|CRSP (CRISPR Therapeutics) - Short-Term Debt to Capital|WGS: Current Liabilities to Capital|RARE (Ultragenyx Pharma) - Short-Term Debt to Equity|BEAM (Beam Tx) - Short-Term Debt to Equity Ratio|Short-Term Debt to Equity Sarepta Therapeutics, Inc. SRPT|Current Liabilities to Equity twistbioscience.com (TWST)|Short-Term Debt to Equity Ratio TXG|Short-Term Debt to Capital NTLA (Intellia Therapeutics Inc)|Short-Term Debt to Equity STOK|BLFS - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Wave Life Sciences (WVE)|MAZE - Ratio of Short-Term Indebtedness to Capital|SION: Short-Term Debt to Capital|Prime Medicine Inc (PRME) - Short-Term Debt to Capital|TSHA: Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient uniQure Pharma (QURE)|MeiraGTx Holdings plc (MGTX) - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital regenxbio.com (RGNX)|Short-Term Debt to Capital SLDB|Ocugen Inc - Short-Term Debt to Capital Coefficient|Pacific Biosciences of California (PACB) - Short-Term Debt to Equity|BNTC - Short-Term Debt to Capital Ratio|DSGN (Design Therapeutics) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio rocketpharma.com|4D Molecular Therapeutics, Inc. (FDMT) - Short-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Lexeo|Korro Bio, Inc. - Short-Term Debt to Capital|Current Liabilities to Capital EDIT (Editas Corp)|Silence Therapeutics - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio ProQR PRQR|Codexis Bio (CDXS) - Short-Term Debt to Capital|SGMO: Short-Term Debt to Capital Ratio|Short-Term Debt to Equity nautilus.bio|Metagenomi Therapeutics (MGX) - Short-Term Debt to Capital Ratio|DTIL (Precision BioSciences) - Short-Term Debt to Capital|Short-Term Debt to Capital Generation Bio Corp (GBIO)|Short-Term Debt to Equity Ratio Boundless Bio|Short-Term Loans to Capital Ratio exicuretx.com (XCUR)|IMNN: Short-Term Debt to Capital|Phio Pharmaceuticals Corp - Current Liabilities to Capital|MBIO: Short-Term Debt to Equity|RNAZ: Short-Term Debt to Equity Ratio|Short-Term Debt to Equity bionanogenomics.com (BNGO)|Current Liabilities to Equity Applied DNA Sciences Inc|BLUE (Bluebird Bio) - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital IPA|OMGA (Omega Therapeutics) - Short-Term Debt to Equity|Short-Term Debt to Capital Coefficient singulargenomics.com OMIC|Short-Term Debt to Equity Ratio Regulus Therapeutics Inc.|Ratio of Short-Term Indebtedness to Capital Syros Pharmaceuticals Inc. SYRS|Codex DNA - Short-Term Debt to Capital|TCON - Short-Term Debt to Capital|Unity Biotechnology - Short-Term Debt to Capital